Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516192 | 1.00 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL6480804 | 1.00 | CYP3A4 (0.42) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3822979 | 0.81 | CYP19A1 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3183323 | 0.81 | CYP19A1 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL2382554 | 0.81 | CYP19A1 (0.40) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL17438169 | 0.81 | TSHR (0.48) | CYP3A4KDM4ETAAR1TSHRHTR3A | |
| SCHEMBL3851200 | 0.80 | TAAR1 (0.60) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL6579025 | 0.79 | CYP3A4 (0.38) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL25314645 | 0.78 | LMNA (0.60) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL294423 | 0.78 | LMNA (0.60) | CYP3A4CYP19A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117776852-A | Method for adsorption separation of propylene and propane | 浙江大学衢州研究院 | 2024-03-29 | — | — | CN | claimed |
| CN-108671893-B | Metal organic framework material for separating ethylene and acetylene and method for separating ethylene and acetylene | 浙江大学 | 2021-03-30 | — | — | CN | claimed |
| CN-107805260-B | Metal complex, adsorbing material, separating material, and method for separating 1, 3-butadiene | 昭和电工株式会社 | 2020-02-14 | — | — | CN | claimed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | claimed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | claimed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | claimed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | claimed |
| US-20050009805-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | claimed |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | SENSORIUM THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050009805-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051277-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-20250243161-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-20240246910-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-20050009805-A1 | Novel quaternary ammonium compounds | SLC10A1, GOT1, ACAT2 | CYP3A4 1588/4885CYP19A1 1595/4885CYP17A1 1128/4885 |
| US-12269800-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-11999694-B2 | Delivery of therapeutic alkaloid compounds | PNMT, HNMT, NNMT | CYP3A4 347/4885CYP19A1 1647/4885CYP17A1 1884/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | CYP3A4 562/4885CYP19A1 714/4885CYP17A1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.